Sequencing the mouse genome is unlikely to provoke a fund-raising spate like that which flowed from the publication of its human counterpart, but Paradigm Therapeutics Ltd. was keen to stress its murine credentials this week when it announced the completion of a £12 million (US$19 million) second-round funding. (BioWorld International)
Renovo Ltd. raised £21 million in a second round funding that should enable it to take two compounds, one for accelerating wound healing and one for preventing scarring, to the end of Phase II studies, and to put another four compounds into Phase I testing. (BioWorld International)
Renovo Ltd. raised £21 million in a second round funding that should enable it to take two compounds, one for accelerating wound healing and one for preventing scarring, to the end of Phase II studies, and to put another four compounds into Phase I testing. (BioWorld International)
Oxford GlycoSciences plc said its lead product, Zavesca, a treatment for Gaucher's disease received marketing authorization from the European Commission and the company plans to launch the product on the European market in the spring. (Bioworld International)
Oxford GlycoSciences plc said its lead product, Zavesca, a treatment for Gaucher's disease received marketing authorization from the European Commission and the company plans to launch the product on the European market in the spring. (Bioworld International)
